Bladder cancer is the 9th most common cause of tumor-related death worldwide 1 and affects approximately 3.4 million people; it resulted in 188 000 deaths in 2015.
However, if the tumor cells migrate into the surrounding tissues, such as sentinel lymph nodes and organs, and spread to distant organs, the 5-year survival rate decreases to 35% and <10%, respectively. 3 Therefore, the early detection of bladder cancer without proximal and distal metastasis is critical to improve the survival of patients with bladder cancer. An important problem associated with bladder cancer screening is that standard methods, such as urinary cytology, ultrasound (sonography) and cystoscopy, remain unsatisfactory due to low accuracy or high invasiveness. For example, urinary cytology is minimally invasive but not so precise (sensitivity: 40%-60% and specificity: 90%-100%), and cystoscopy is the reverse. Indeed, even for flexible cystoscopy, the risk of developing a urinary tract infection is approximately 10%. 4 Thus, more effective and less invasive diagnostic tools for bladder cancer are urgently needed.
MicroRNA (miRNA) are small non-coding RNA made up of [18] [19] [20] [21] [22] [23] [24] base pairs with single chain molecules. 5, 6 MiRNA modulate gene expression by decreasing target mRNA stability or repressing translational efficiency. They can stably exist in severe conditions, including urine, because some of the miRNA are at least partly packaged into extracellular vesicles or included by an RNA-induced simple complex (RISC) with the Agonature2 protein to protect against the elimination of RNase. [7] [8] [9] Therefore, circulating miRNA, so-called extracellular miRNA, has garnered a great deal of attention as a novel target of liquid biopsy. Recently, we demonstrated the diagnostic potential of circulating miRNA in body fluids, such as breast cancer, ovarian cancer and bladder cancer. [10] [11] [12] Several other research groups have performed large-scale randomized controlled trials and confirmed the diagnostic value in independent research cohorts of bladder cancer. 13, 14 Here, we analyzed 972 serum samples, including 392 bladder cancer samples, 100 non-cancer control samples and 480 samples of other types of tumors, by performing a comprehensive miRNA microarray. In the training set, we identified 7 miRNA candidates for bladder cancer screening. In particular, a single miRNA, miR-6087, showed high diagnostic performance for bladder cancer screening.
Furthermore, the combination of 7 miRNA (7-miRNA panel) clearly discriminated bladder cancer from non-cancer controls and other types of cancer, regardless of cancer stage and grade, enabling the specific and early detection of bladder cancer with high accuracy. and 2016 and stored at −20°C. Details are described in Appendix S1.
| MATERIAL AND ME THODS

| Patients and sample preparation
| Micro RNA expression analysis using microarray
Total RNA was extracted from a 300-μL serum sample using 3D-Gene RNA extraction reagent from a liquid sample kit (Toray Industries, Kanagawa, Japan) and purified with the RNeasy 96 QIAcube HT Kit (Qiagen, Hilden, Germany). Comprehensive miRNA expression analysis was performed using a 3D-Gene miRNA labeling kit and a 3D-Gene
Human miRNA Oligo Chip (Toray Industries), which was designed to detect 2565 miRNA sequences registered in miRBase release 21. 15 To normalize the signals among the microarrays tested, we pre-selected 3 internal control miRNA (miR-149-3p, miR-2861 and miR-4463) 10 The usability of these internal control miRNA were confirmed in the present dataset (Table S1 ). All microarray data of this study are publicly available through the GEO database (GSE113486). Details are described in Appendix S1.
| Quantitative RT-PCR
The miRNA expression levels were investigated using miScript Primer Assays (Qiagen) with the miScript II RT Kit, the miScript PreAMP PCR Kit and the miScript SYBR Green PCR Kit. Details are described in Appendix S1.
| Statistical analysis
The samples of each clinical condition were independently divided into the training cohort and the validation cohort. With the training cohort, a χ 2 test for categorical variables or an unpaired t test for continuous variables was used to compare the characteristics between the 2 clinical groups. Fisher's linear discriminant analysis was performed in the training cohort, and the diagnostic sensitivity, specificity and accuracy were calculated for each miRNA marker or a combination of miRNA markers in the training/validation cohort. When expressions of multiple miRNA were used in the algorithm development, the discriminant functions were created using Fisher's linear discriminant analysis. The resulting values of the discriminant functions were used to prepare the diagnostic index. In clinical samples, an index score of 0 or more was considered to indicate bladder cancer, and an index score of <0 was considered to indicate non-bladder cancer or other clinical conditions.
Details are described in Appendix S1.
| Ethical statement
The present study involving human subjects was approved by: a training set and a validation set. In each set, 192 bladder cancer patients, 50 non-cancer controls and 240 other types of cancer samples were included ( Figure 1A ). Participants' characteristics are described in Table 1 . There was no statistically significant difference in the clinicopathological characteristics, including gender, pathological T stage and pathological grade (Table 1) , between the 2 different cohorts. In the miRNA microarray, expression levels of 2565 miRNA were comprehensively examined.
To identify miRNA biomarker candidates, we focused on highly detected miRNA (≥2 6 of normalized levels in signal intensity at least in the analyses of more than half in each clinical group). The 386 miRNA that were considered to represent high detection were applied for Fisher's linear discriminant analysis in the training set ( Figure 1B ). The diagnostic performance of these models (single miR- 
| Comparison of bladder cancer and other types of cancers using the diagnostic index
We next attempted to investigate the diagnostic performance of 97%; Figure S4A ,B). The data also indicated that the 7-miRNA panel had higher accuracy than urinary cytology.
F I G U R E 2
Receiver operating characteristic (ROC) curve analysis of miR-6087, 7-miRNA panel and 2 confirmed miRNA panel in the training set and the validation set. A, ROC curves for detecting bladder cancer patients using miR-6087, 7-miRNA panel and 2 confirmed miRNA panel selected for diagnostic models in the training set. B, ROC curves of miR-6087, 7-miRNA panel and 2 confirmed miRNA panel in the validation set
We also designed the model to distinguish between <pT2 (n = 300) and ≥pT2 (n = 90), by separating a training set and a validation set. As shown in Table S2 , we selected the best miRNA combination based on Fisher's linear discriminant analysis, which is the same approach for identifying the 7-miRNA panel for bladder cancer discrimination. In the training set, the best model showed an AUC of .70, and in the validation set, it showed an AUC of .59 ( Figure S5A ). Using this model, we attempted to distinguish between bladder cancer samples and other controls (healthy and other cancers); however, the discrimination performance is actually much lower (AUC: .61, Figure S5B ).
| D ISCUSS I ON
In this study, the levels of serum miR-6724-5p, miR-1185-1-3p
and miR-6831-5p were significantly elevated, and those of test, our model had much higher sensitivity and specificity. [16] [17] [18] In the training and validation sets, the 7-miRNA panel in bladder cancer showed high sensitivity (95%-98%) and specificity (87%-91%), whereas another typical tumor detection method, urinary cytology, which is also a low-invasiveness test, had 48% sensitivity and 86% specificity. 19 Notably, the 7-miRNA panel in bladder cancer is also effective for the detection of both low and high grades (92.7% and 96.1% in sensitivity, respectively), Recently, the molecular characterization of cell-free DNA, circulating tumor DNA and circulating miRNA by liquid biopsy is an attractive alternative to tissue biopsy to diagnose cancer and other diseases. [13] [14] [15] [20] [21] [22] [23] For diagnosis of bladder cancer by liquid biopsy, there are several reports of biomarker searches with large samples, including those detecting tumor-specific hotspot mutations in serum F I G U R E 4 Diagnostic performance of the discriminants in other types of cancers. A-C, Diagnostic index was calculated and plotted in a dot plot among 12 different cancers (BC, breast cancer; BT, biliary tract cancer; CC, colorectal adenocarcinoma; EC, esophageal squamous cell carcinoma; GC, gastric adenocarcinoma; GL, glioma; HC, hepatocellular carcinoma; LK, lung carcinoma; OV, ovarian cancer; PC, pancreatic cancer; PR, prostate cancer; SA, bone and soft tissue sarcoma) for the discriminants. An index score ≥0 indicated bladder cancer and an index score <0 indicated the absence of bladder cancer. Each positive rate is shown in the plot DNA or miRNA in urine from patients. 20, 21 For the study of serum miRNA, a few studies have investigated the potential of miRNA detection in serum for biomarkers in bladder cancer. [13] [14] [15] Most of these previous reports have performed microarray or next-generation sequencing with serum miRNA samples from patients diagnosed with bladder cancer and control individuals (non-cancer controls) to detect preclinical bladder cancer. A unique aspect of our study is that the 7-miRNA panel and 2 confirmed miRNA panel could distinguish bladder cancer patients from 12 other types of solid tumors. In addition, the diagnostic performance of both panels for non-muscle invasive bladder cancer (T stage <pT2) could reach an accuracy >90% in the diagnostic index. Because bladder cancer occurs in normal urothelial cells and does not invade muscle from the beginning, both panels could detect non-muscle invasive bladder cancer. However, both panels could not separate non-muscle and muscle invasive bladder cancer, which is most valuable information for deciding whether cystectomy is performed or not.
In addition, urinary cytology, which has high specificity but low sensitivity, is commonly used for detecting bladder cancer. In the bladder cancer group, many cases also had not been captured by urinary cytology (Table 1) . However, the 7-miRNA panel could be an effective biomarker in bladder cancer patients with negative urinary cytology. In particular, urologists have been unsure of whether to diagnose class III cases as bladder cancer. They are reported as atypical cells with low-grade bladder cancer potential. 24 In Figure S4B , class III is included in the malignant group (class III-V) because most urologists actively observe and/or re-examine class III cases.
Unexpectedly, we found that a single miRNA, miR-6087, had remarkably high diagnostic power, with an AUC of .89, sensitivity of 93% and specificity of 77% for detecting individuals with Although this evidence highlights the important roles of serum miRNA in the biomarker discovery, there are a few criticisms of the present study. One of these issues is that all microarray experiments to generate miRNA profiles were conducted with the serum miRNA samples, which were retrospectively collected in the hospitals. All serum samples from cancer patients were collected in the NCCH.
However, non-cancer samples were collected from different hospitals. Before performing the microarray analysis, it was evident that there were inconsistencies in the time intervals for sample preparation, storage periods and storage temperatures, which were not strictly regulated among hospitals. The stability of miRNA in body fluid could affect the sample quality and miRNA expression levels. 27, 28 Furthermore, the storage procedures for non-cancer samples were not consistent among facilities. To minimize bias of the results, we also included serum samples of patients with the other cancers in the control group, which were collected in the same facility using the same methods as for bladder cancer samples.
Therefore, although we believe that we successfully constructed a bladder cancer-specific diagnostic model, further validation studies are needed. In addition, the method of selection of control samples to distinguish bladder cancer is open to debate. In this study, we prepared serum samples from healthy individuals and other types of cancer samples as controls; however, it could be better to use at-risk samples of bladder cancer such as patients with hematuria as controls. For comparison of the serum samples between bladder cancer patients and patients at risk of bladder cancer and to further confirm our data in this work, we have started a prospective trial in the clinical setting, and the analysis of fresh blood samples will assist in standardizing our models for bladder cancer screening and surveillance in the coming years. Another limitation is that the origins of the 7 miRNA and their functions in bladder cancer are totally unknown.
Because the miRNA that we found to be bladder cancer biomarkers are relatively newly discovered miRNA, there is almost no literature on them in relation to cancer biology.
It is important to consider whether the present study confirmed orthogonal validation for microarray data using miRNA-seq or qRT-PCR. We previously performed miRNA-seq and microarray analysis using the same 20 serum samples stocked in NCC Biobank (unpub- Because, for PCR quantification, the sequence needs to be perfectly matched to the primer designed, the validation and microarray data often had differences. Thus, qRT-PCR methods might not be suitable for the validation of microarray results. However, we performed qRT-PCR for validation to confirm the expression levels of the internal control and to compare the expression levels of candidate miRNA between bladder cancer and other types of cancer. The former, the internal control miRNA (miR-149-3p, miR-2861 and miR-4463), had stable expression in each sample, and our microarray performance had accurate data. The latter, 2 miRNA (miR-6087 and miR-1343-5p), had similar expression as for the microarray analysis ( Figure S1B ). Although PCR quantification might not be suitable for validation of microarrays, our
qRT-PCR analysis tended to present similar results as for microarrays.
Taken together, the data presented in this study suggest that both panels could detect early-stage and both high-grade and low-grade bladder cancers using a small quantity of blood samples, and that the method is clinically feasible and valuable for the surveillance of bladder cancer in at-risk groups. Our microarray-based serum miRNA detection method is based on techniques including serum collection, miRNA extraction and miRNA microarray, which are robust and simple experimental procedures. Thus, miRNA-based bladder cancer detection should be useful for the primary screening and surveillance of bladder cancer and should become prevalent in clinical settings.
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